Jan 18, 2013, 08.15 AM | Source: Moneycontrol.com
On January 17, 2013 Ramjidas & Sons sold 350,000 shares of Ajanta Pharma at Rs 399.44 on the NSE and sold 150,000 shares at Rs 397.50 on the BSE.
However, RBA Finance And Invest Co bought 150,000 shares at Rs 397.50 on the BSE and bought 350,000 shares at Rs 399.44 on the NSE.
In the previous trading session, the share closed at Rs 406.75, up Rs 14.60, or 3.72%. It has touched an intraday high of Rs 409 and an intraday low of Rs 390.
The company's trailing 12-month (TTM) EPS was at Rs 62.81 per share. (Sep, 2012). The stock's price-to-earnings (P/E) ratio was 6.48. The latest book value of the company is Rs 116.05 per share. At current value, the price-to-book value of the company was 3.5. The dividend yield of the company was 0.92%.
The share touched its 52-week high Rs 505 and 52-week low Rs 162.35 on 21 September, 2012 and 18 January, 2012, respectively. Currently, it is trading 19.46% below its 52-week high and 150.54% above its 52-week low. Market capitalisation stands at Rs 952.49 crore.
Sudarshan Sukhani of s2analytics.com is of the vie
The company had posted a profit of Rs 86.01 crore
The company has launched the product in the US thr
Ashwani Gujral of ashwanigujral.com recommends buy
Ajanta Pharma announced the final approval from US